Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory …
$7.52-3.47%
报价 2026-11-13
市值
$102.6M
EV
$-57.2M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -55.5%
$5.10$16.90
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| IMUXImmunic, Inc. | $102.6M | -3.5% | -96.9% | 0% | – | – | – | |
| RLMDRelmada Therapeutics, Inc. | $449.1M | +1.2% | +300.0% | 0% | – | – | – | |
| CBUSCibus, Inc. | $86.4M | +3.7% | +90.0% | 72.1% | – | – | – | |
| PMVPPMV Pharmaceuticals, Inc. | $67.7M | +5.0% | – | 0% | – | – | – | |
| ACRVAcrivon Therapeutics, Inc. Common Stock | $62.1M | -0.7% | +1400.0% | 0% | – | – | – | |
| BMEABiomea Fusion, Inc. | $42.3M | +3.5% | +20.0% | 0% | – | – | – | |
| ACETAdicet Bio, Inc. | $26M | -5.1% | 0.0% | 0% | – | – | – | |
| LITSLite Strategy, Inc. | $25.3M | -6.6% | 0.0% | 0% | – | – | – | |
| TCRXTScan Therapeutics, Inc. | $10.2M | -4.4% | -32.1% | 90.3% | – | – | – | |
| 同行中位数 | – | – | +20.0% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。